mercredi 11 décembre 2019

Onco Actu du 11 décembre 2019


1.1.1 BIOLOGIE - GÉNOME - MÉTASTASES



Researchers identify gene behind spread of deadly breast cancer [Cold Spring Harbor Lab]











4.10 DÉP., DIAG. & PRONO. - POUMON



Biomarker-Driven Staging—Are We There Yet? [JAMA Network Open]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



Are we Ready for DNA-based Population Screening? The Need for Large Collaborative Pilot Studies [Genomics and Precision Health - CDC]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



China’s Curing Cancer Faster and Cheaper Than Anywhere Else [Bloomberg]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans [Biopharma Dive]










5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials [ImmunOs Therapeutics]











5.16 TRAITEMENTS - CHIRURGIE



Surgery for Recurrent Ovarian Cancer Does Not Improve Survival [NCI]










5.17 TRAITEMENTS - RADIOTHÉRAPIE



ASTRO issues new clinical guideline on radiation therapy for basal and squamous cell skin cancers [ASTRO]











5.2 PHARMA



CEO Paul Hudson has sharp words for Sanofi's mistakes—and a pointed plan he thinks will fix them [Fierce Pharma]











Leukemia rivals try to stay ahead as Merck, Lilly chase [Biopharma Dive]











Paul Hudson promises a bright new future at Sanofi, kicking loose me-too drugs and focusing on landmark advances. But can he deliver? [EndPoints]











5.2.1 PHARMA - PARTENARIATS



AstraZeneca brings AI to molecule building with DeepMatter deal [Fierce Biotech]











AbbVie, Scripps expand partnership, fortify focus on cancer drugs [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Do large pharma companies provide drug development innovation? Our analysis says no [STAT]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Is the number of cancer drug approvals a surrogate for regulatory success? [Journal of Cancer Policy]











5.4 TRAITEMENTS - ECONOMIE



Targeted ovarian cancer drug made more widely available on the NHS in Scotland [Cancer Research UK]











5.8 ASH



ASH 2019 Roundup: The Latest on CAR T, New Treatments for CLL, and Using Genes to Predict a Common Side Effect [Memorial Sloan Kettering Cancer Center]











5.8.3 ASH - DIVERS



ASH Study Points to Distinct AML, MDS Subtypes Based on Genomic, Transcriptomic Analysis [Genome Web]











Study Reveals Genetic Underpinnings of AML and Myelodysplastic Syndrome [ASH]










5.8.5 ASH - MYÉLOME MULTIPLE



ASH: Bluebird's multiple myeloma CAR-T follow-up shows promise in phase 1 [Fierce Biotech]











DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma [Janssen]











Triple Drug Combination Delays Disease Progression in People with Stubborn Multiple Myeloma [ASH]











5.8.6 ASH - LEUCÉMIES



Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001 [BMS]











Immunotherapy drug improves outcomes for some children with relapsed leukemia [NIH]










Immunotherapy Superior to Chemotherapy for Children with Relapsed B-ALL [ASH]











New Drug Markedly Improves Overall Survival in Patients with AML in Remission [ASH]











6.1 OBSERVATION



The gene-based hack that is revolutionizing epidemiology [Nature]










6.6 PUBLICATIONS



Raising research quality will require collective action [Nature]











6.8 COMMUNICATION



The Hype Problem [In The Pipeline]